title: Protection against post-ischemic behavioral pathology by the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) in the gerbil.
abstract: The neuroprotective effects of NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline) were assessed on hippocampal CA1 neuronal loss and locomotor hyperactivity following transient bilateral carotid artery occlusion (BCAO) in the gerbil. NBQX, a selective blocker of the AMPA glutamate receptor subtype, was injected 1 h after 5 or 10 min BCAO, or sham surgery. Both 5 and 10 min ischemia produced equivalent hyperactivity 3 days post ischemia and CA1 neuronal loss on Day 4, while activity was unchanged in the sham-operated group. NBQX protected from both hippocampal damage and post-ischemic hyperactivity. These results demonstrate that NBQX can protect from behavioral pathology induced by global cerebral ischemia.
authors.affiliation: Novo Nordisk A/S, CNS Division, Soeborg, Denmark.
authors.forename: M E
authors.initials: ME
authors.lastname: Judge
authors.forename: M J
authors.initials: MJ
authors.lastname: Sheardown
authors.forename: P
authors.initials: P
authors.lastname: Jacobsen
authors.forename: T
authors.initials: T
authors.lastname: Honoré
mesh_terms: D000818:Animals; D005849:Gerbillinae; D006624:Hippocampus / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D002546:Ischemic Attack, Transient / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D009474:Neurons / Q000187:drug effects / Q000473:pathology* / Q000502:physiology; D011712:Pyramidal Tracts / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D011810:Quinoxalines / Q000494:pharmacology* / Q000627:therapeutic use; D018091:Receptors, AMPA; D017981:Receptors, Neurotransmitter / Q000037:antagonists & inhibitors*
chemical_list: D011810:Quinoxalines; D018091:Receptors, AMPA; D017981:Receptors, Neurotransmitter; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline